The findings suggest weight loss drugs independently affect heart health risks, researchers said. View on euronews ...

The San Diego-based biotech has been evaluating the oral NLRP3 inhibitor, dubbed VTX3232, in a phase 2 study of 175 patients ...

Regardless of how much weight you lose, GLP-1 drugs like Wegovy and Ozempic could decrease major adverse cardiovascular ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

A new drug being trialed in heart attack patients could reprogram the immune system to prevent inflammation and heart damage ...

The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

Semaglutide reduces cardiovascular events by 23% and direct heart disease death risk by 26% compared to dulaglutide in older ...

A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against ...

Researchers found cardiovascular drugs were associated with 24.7 percent of all medication errors, followed by antibiotics at 19.1 percent, electrolytes at 11.3 percent, endocrine drugs at 8.8 percent ...

In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.

In the study, published Tuesday in the journal The Lancet, researchers analyzed more than 58,000 participants to compare 30 ...